“What’s New Doc?” in Lung Cancer

Join us for insightful updates on the forefront of lung cancer research with our new series, “What’s New Doc?” in Lung Cancer. Each week, experts in the field will share comprehensive information and provide fresh perspectives on the latest data, offering valuable insights into lung cancer treatment and research.

Explore a diverse range of cutting-edge communication as we bring you the most recent advancements in lung cancer research. Stay tuned for weekly updates that promise to enhance your understanding of the evolving landscape in lung cancer treatment.

Episode 4: The MARIPOSA trial

This phase 3 trial randomized treatment-naïve NSCLC patients with classic EGFR mutations (ex19del or L858R) between SOC osimertinib and lazertinib, another third-generation EGFR TKI with excellent brain penetration, and a third arm combining amivantamab with lazertinib. Amivantamab is a novel

See video »

Episode 2: The FLAURA2 trial

Prof Mariana Brandao and Prof Johan Vansteenkiste discuss the FLAURA2 trial presented at WCLC2023, a recent study in EGFR-mutated NSCLC that holds clinical significance.

Osimertinib currently stands as the standard treatment for treatment-naïve patients with EGFR-mutated lung tumours, demonstrating high

See video »

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy